PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Virus Res. Author manuscript; available in PMC 2008 November 13.
Published in final edited form as:
PMCID: PMC2582734
NIHMSID: NIHMS77060

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein

Abstract

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is the cause of an atypical pneumonia that affected Asia, North America and Europe in 2002–2003. The viral spike (S) glycoprotein is responsible for mediating receptor binding and membrane fusion. Recent studies have proposed that the carboxyl terminal portion (S2 subunit) of the S protein is a class I viral fusion protein. The Wimley and White interfacial hydrophobicity scale was used to identify regions within the CoV S2 subunit that may preferentially associate with lipid membranes with the premise that peptides analogous to these regions may function as inhibitors of viral infectivity. Five regions of high interfacial hydrophobicity spanning the length of the S2 subunit of SARS-CoV and murine hepatitis virus (MHV) were identified. Peptides analogous to regions of the N-terminus or the pre-transmembrane domain of the S2 subunit inhibited SARS-CoV plaque formation by 40–70% at concentrations of 15–30 μM. Interestingly, peptides analogous to the SARS-CoV or MHV loop region inhibited viral plaque formation by >80% at similar concentrations. The observed effects were dose-dependent (IC50 values of 2–4 μM) and not a result of peptide-mediated cell cytotoxicity. The antiviral activity of the CoV peptides tested provides an attractive basis for the development of new fusion peptide inhibitors corresponding to regions outside the fusion protein heptad repeat regions.

Keywords: Severe acute respiratory syndrome-associated coronavirus, Class I viral fusion protein, Peptide inhibitor, Murine hepatitis virus, Six-helix bundle, Anti-viral

1. Introduction

Severe acute respiratory syndrome (SARS) is an atypical pneumonia characterized by influenza-like symptoms including fever, cough, dyspnea and headache. The epidemic of 2002–2003 produced an overall mortality of approximately 10%, resulting in 774 deaths in 29 countries world-wide (Goldsmith et al., 2004; Holmes, 2005; Peiris et al., 2003b). The etiological agent of SARS (SARS-CoV) was quickly identified as belonging to the family Coronaviridae, a group of large enveloped RNA viruses exhibiting a broad host range and capable of causing respiratory, hepatic and enteric diseases (Lai and Holmes, 2001; Siddell, 1995). Initial phylogenetic analyses and sequence comparisons revealed significant differences between SARS-CoV and other CoVs, distinguishing it as a unique group (group 4), unrelated to previously characterized CoV groups 1–3 (Drosten et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003a). More recent analyses, however, report that SARS-CoV more closely resembles group 2 CoV and should therefore be classified as a subgroup within group 2 (Gorbalenya et al., 2004; Magiorkinis et al., 2004; Song et al., 2005). Further phylogenic analyses and studies investigating the ancestral origins of SARS-CoV should yield a consensus regarding its proper grouping. Nonetheless, as animal reservoirs of SARS-CoV appear to exist, reemergence of this unique CoV is highly probable and therefore the threat of a new SARS outbreak remains a constant public health concern.

Like other enveloped viruses, CoVs enter target cells by inducing fusion between the viral and cellular membranes, a process mediated by the viral spike (S) glycoprotein (Gallagher and Buchmeier, 2001). The S1 subunit of the S protein mediates receptor binding (Cavanagh and Davis, 1986; Taguchi, 1995), while the S2 subunit is responsible for driving viral and target cell membrane fusion (Taguchi and Shimazaki, 2000). In the case of SARS-CoV, the S1 subunit binds to the mammalian receptor angiotensin-converting enzyme 2 (ACE2) (Huang et al., 2006; Li et al., 2003, 2005; Wang et al., 2004; Wong et al., 2004) and/or CD209L (Jeffers et al., 2004), initiating the entry process via a cathepsin L-dependent pathway (Huang et al., 2006). Analysis of the murine hepatitis virus (MHV) and SARS-CoV S proteins (Li et al., 2005; Xu et al., 2004a,b,c) reveal common structural features shared with class I viral fusion proteins (Gallaher, 1996; Gallaher et al., 1989), including a hydrophobic fusion peptide (Sainz et al., 2005b), a pair of extended α helices (N-helix and C-helix) (Tripet et al., 2004), a loop domain separating the two α helices and a cluster of aromatic amino acids (Sainz et al., 2005a) proximal to a hydrophobic transmembrane anchoring domain. Class I viral fusion proteins mediate viral and target cell membrane fusion through a series of conformational changes involving insertion of a fusion peptide into the target cell membrane, trimerization and extension of the heptad repeat (HR) helices toward the target membrane and the subsequent formation of a six-helix coiled-coil bundle (Gallaher, 1987). In this structure, a trimer of HR1 helices forms a central coiled-coil surrounded by three HR2 helices in an anti-parallel mode (Xu et al., 2004b). The loop region is believed to act as a hinge, facilitating six-helix coiled-coil bundle formation and mediating membrane juxtaposition.

While current models of viral:cell membrane fusion are hypothetical in most aspects, the importance of several of the structural/functional motifs of class I viral fusion proteins as drug development targets has been established. For example, analogs of the orthomyxovirus, paramyxovirus (Richardson et al., 1980) and HIV-1 fusion peptide domains (Gallaher et al., 1992; Owens et al., 1990; Silburn et al., 1998) block viral infection, presumably by forming inactive heteroaggregates. Likewise, peptides analogous to the HR regions of the HIV-1 (Gallaher et al., 1992; Qureshi et al., 1990; Wild et al., 1992, 1993), paramyxovirus (Lambert et al., 1996; Young et al., 1999) or Ebola virus (EboV) (Watanabe et al., 2000) class I viral fusion proteins block virion infectivity by preventing the transition of the fusion protein into the six-helix bundle state. The anti-HIV-1 peptidic drug Fuzeon™ (DP178, T-20 or enfuvirtide), which overlaps HR2 and the aromatic domain of gp41, was the first of a new class of fusion inhibitor antivirals to gain FDA approval (2003). This peptide has been shown to potently inhibit HIV-1 virion:cell fusion at very low concentrations (50% inhibition at 1.7 nM) in vitro (Wild et al., 1993). Likewise, in clinical trials, 100 mg/day of Fuzeon™ caused an ~ 100-fold reduction in plasma HIV-1 load of infected individuals (Kilby et al., 1998; Lalezari et al., 2003a,b). These results substantially validate the efficacy of this new class of antivirals and have greatly motivated the search for peptide fusion inhibitors designed to target other viruses, such as SARS-CoV (Gallaher and Garry, 2003; Kliger and Levanon, 2003).

To date, studies examining peptide fusion inhibitors of CoV have only examined the efficacy of peptides analogous to the HR regions of the viral fusion protein. Bosch et al. (2003) first demonstrated that a peptide analogous to the HR2 helix of the MHV S2 subunit could block viral entry at concentrations of 10–50 μM. Several other groups later showed that HR1 and/or HR2 peptides could likewise inhibit SARS-CoV entry and replication (Bosch et al., 2004; Liu et al., 2004; Yuan et al., 2004; Zhu et al., 2004). The antiviral capacity of these peptides is attributed to the inherent interactions between HR1 and HR2 (Tripet et al., 2004; Xu et al., 2004b,c). Peptides analogous to either one of the two HR regions are believed to directly inhibit endogenous HR1 and HR2 interactions, preventing formation of the six-helix bundle.

Although the HR analogs appear to be effective inhibitors of SARS-CoV entry in vitro, development of other peptide fusion inhibitors, based on non-HR regions of the viral fusion protein, has yet to be explored. Here we employed a novel approach to identify new peptide inhibitors of SARS-CoV. Using the Wimley and White (WW) interfacial hydrophobicity scale (IHS) (Wimley and White, 1996), we identified five regions within the SARS-CoV and MHV S2 subunit with a high propensity to interact with the lipid interface of membranes. These regions, spanning the entire S2 subunit, may play an important role in viral fusion protein:target cell membrane interactions and may therefore represent possible targets for therapeutic interference. Our results demonstrate that peptides analogous to these regions of high interfacial hydrophobicity are effective inhibitors of SARS-CoV infectivity. In particular, peptides analogous to the loop region and/or the N-terminal region of the S2 subunit potently inhibit CoV plaque formation by 70–90% at concentrations of 30 μM or less (~100 μg/ml). These findings provide an alternative approach to the development of viral peptide inhibitors, allowing for the identification of other possible therapeutic peptides outside of the HR regions of class I viral fusion proteins.

2. Materials and methods

2.1. Peptide synthesis

The MHV and SARS-CoV synthetic peptides were synthesized by solid-phase methodology using a semi-automated peptide synthesizer and conventional N-alpha-9-fluorenylmethyloxycarbonyl chemistry by Genemed Synthesis Inc. (San Francisco, CA). Peptides were purified by reversed-phase high performance liquid chromatography, and their purity confirmed by amino acid analysis and electrospray mass spectrometry. Peptide stock solutions were prepared in 10% dimethyl sulfoxide (DMSO, spectroscopy grade): 90% H2O (v/v), and concentrations determined spectroscopically (SmartSpec™ 3000, BioRad, Hercules, CA).

2.2. Cells and viruses

Vero E6 and L2 cells (American Type Culture Collection, Manassas, VA) were maintained in minimum essential medium (MEM) or Dulbecco modified Eagle medium (DMEM), respectively, and supplemented with 5% fetal bovine serum (FBS), penicillin G (100 U/ml), streptomycin (100 mg/ml) and 2 mM l-glutamine, at 37 °C in 5% CO2. SARS-CoV strain Urbani was propagated in Vero E6 cells, and MHV strain A59 (ATCC, VR764) was propagated in L2 cells.

2.3. Viral plaque reduction assays

For plaque reduction assays, Vero E6 cells or L2 cells were seeded at a density of 1 × 106 cells in each well of a 6-well plate 24 h (h) prior to infection. Approximately 50 plaque forming units (PFU) of either SARS-CoV strain Urbani or MHV were pre-incubated with peptide or without peptide (diluent control) in serum-free MEM (SARS-CoV) or serum-free DMEM (MHV) for 1 h at 37 °C. Vero E6 or L2 cells were then infected with (1) peptide- or vehicle-treated SARS-CoV inoculum or (2) peptide- or vehicle-treated MHV inoculum, respectively. After 1 h adsorption, the inoculum was removed, cells were washed twice with 1× phosphate buffered saline (PBS), and then overlaid with 10% FBS/MEM or 10% FBS/DMEM, both containing 0.5% Noble Agar (Sigma, Rockland, ME). L2 cells were fixed 2 days p.i. with 3.7% formalin for 2 h at room temperature and then stained with 1× crystal violet to visualize plaques. Vero E6 cells were stained with neutral red 3 days p.i. and plaque numbers were determined 24 h later.

2.4. Cell viability assay

Cell viability was determined by using the TACS™ MTT Assay (R&D Systems Inc., Minneapolis, CA) according to the manufacturer's instructions. Briefly, Vero E6 cells or L2 cells were seeded at a density of 4 × 105 cells in each well of a 96-well plate 24 h prior to treatment. Cells were subsequently treated with medium, diluent-control or 100 μg/ml (~30 μM) of peptide for 2 h prior to the addition of the tetrazolium compound MTT. Following incubation and subsequent addition of detergent, absorbance was read at 570 nm with a spectrophotometer.

2.5. CD spectroscopy

CD spectra were recorded on a Jasco J-810 spectropolarimeter (Jasco Inc., Easton, MD), using a 1 mm path length, 1 nm bandwidth, 16 s response time and a scan speed of 10 nm/min. All CD runs were performed at room temperature with 50 μM peptide dissolved in 10 mM phosphate (PO4) buffer at pH 7.0. Three successive scans between 190 and 250 nm were collected and the CD data are expressed as the mean residue ellipticity, derived from the formula Θ = (deg × cm2)/dmol.

2.6. Proteomics computational methods

Methods to derive general models of surface glycoproteins have been described previously (Gallaher et al., 1989). Domains with high interfacial hydrophobicity were identified with Membrane Protein eXplorer (MPeX; Stephen White laboratory; http://blanco.biomol.uci.edu/mpex). MPeX detection of membrane spanning sequences is based on experimentally determined hydrophobicity scales (White and Wimley, 1999; Wimley and White, 1996).

2.7. Statistics

Data are presented as the mean ± standard error of the means (S.E.M.). Data from peptide-treated groups were compared to vehicle-treated groups and significant difference were determined by one-way analysis of variance (ANOVA) followed by Tukey's post hoc t-test (GraphPad Prism©, San Diego, CA).

3. Results

3.1. Identification of peptides analogous to the CoV S2 subunit

Previous studies of potential peptide inhibitors of CoV have only examined the efficacy of peptides corresponding to the α helical regions (HR regions) of the S2 subunit (Bosch et al., 2004; Liu et al., 2004; Yuan et al., 2004; Zhu et al., 2004). Development of additional peptide fusion inhibitors, based on domains of the viral fusion protein other than the prominent α helices, has yet to be explored. We used a computational approach to identify regions of the SARS-CoV fusion protein that potentially interact with bilayer membranes (Wimley and White, 1996). The WWIHS is an experimentally-determined algorithm that can be used to estimate the propensity of an amino acid sequence to interact with the lipid membrane interface (Wimley and White, 1996). Five regions of high interfacial hydrophobicity within the SARS-CoV S2 region were identified using Membrane Protein eXplorer (MpeX) (http://blanco.biomol.uci.edu/mpex/), a computer program based on the WWIHS (Fig. 1A). WW-I and WW-II peptides correspond to the amino-terminus of the S2 region, predicted to contain the fusion peptide (Sainz et al., 2005b). WW-III and WW-IV peptides correspond to the loop domain and the WW-V peptide corresponds to the aromatic domain. The latter is a highly conserved region among the Coronaviridae family and is also present in class I viral fusion proteins of otherwise disparate RNA viruses, such as HIV-1 and EboV (Sainz et al., 2005a). The transmembrane domain of the S2 region also scored high on the WWIHS (Fig. 1A), but was not investigated as it is anchored within the viral membrane and not exposed during viral entry. Although the SARS-CoV S protein shares only 20–27% amino acid sequence similarity with the S protein of MHV (Rota et al., 2003), five analogously located sequences of high interfacial hydrophobicity were identified in the S2 subunit of MHV strain A59 (Fig. 1B) and strain BHK (data not shown).

Fig. 1
(A) Interfacial hydrophobicity plot corresponding to sequences of the SARS-CoV strain Urbani S2 subunit (amino acids 758–1255). (B) Interfacial hydrophobicity plot corresponding to sequences of the MHV strain A59 S2 subunit (amino acids 780–1324). ...

3.2. Identification of peptide inhibitors of CoV infectivity

Synthetic peptides corresponding to the sequences with significant WWIHS scores were synthesized (Table 1) and examined for their ability to inhibit either SARS-CoV plaque formation on Vero E6 cells, at peptide concentrations of ~30 μM (Fig. 2). SARSWW-I and SARS-WW-II inhibited viral plaque formation by 58 and 39%, respectively. SARSWW-Va, however, did not show any inhibitory effect at this concentration. This peptide was of particular interest as it was modeled after the HIV-1 peptide inhibitor, Fuzeon™ (Kilby et al., 1998) and corresponds to the C-terminus of the C-helix and the aromatic domain. Previous work from our laboratory has shown that the aromatic domain of both the SARS-CoV and MHV S2 subunit partition into the membranes of lipid vesicles and are capable of compromising membrane integrity (Sainz et al., 2005a). We hypothesized that the inability of SARSWW-Va to inhibit SARS-CoV entry may be due to its propensity to partition into the lipid interface (Sainz et al., 2005a). A WW-V derivative with a five amino acid truncation of the aromatic domain (SARSWW-Vb, Table 1) was capable of inhibiting SARS-CoV plaque formation by 42% (Fig. 2A). Peptides corresponding to the loop region of the SARS-CoV fusion protein were the most effective at inhibiting SARS-CoV plaque formation. SARSWW-III and SARSWW-IV inhibited viral plaque formation by 90 and 83%, respectively (Fig. 2A). Shown in Fig. 2B–D is a representative photograph of SARS-CoV plaque formation in the presence of these two peptides. Consistent with the experimental results presented in Fig. 2A, SARS-CoV plaque efficiency was significantly inhibited in the presence of SARSWW-III and SARSWW-IV, as compared to vehicle-treated controls (Fig. 2C–D versus B).

Fig. 2
Effect of peptides analogous to the viral S protein on SARS-CoV plaque formation. (A) Vero E6 were infected with virus pre-incubated for 1 h with 30 μM peptide. Cells were subsequently infected for 1 h, overlaid with medium containing 0.5% agarose ...
Table 1
Amino acid sequences of peptides corresponding to sequences of the S2 subunits of SARS-CoV or MHV with significant WWIHS scores

To confirm that the observed anti-viral activity of the peptides tested was not a consequence of cellular cytotoxicity, a MTT assay was performed as described in Section 2.4. Cells were treated with the tetrazolium compound MTT, which is reduced by metabolically active viable cells to purple formazan dye crystals. Absorbance (OD570) of solubilized crystals in peptide-treated or diluent-treated groups can be compared to untreated controls. Vero E6 cells treated with ~30 μM of SARS-CoV peptides showed no difference in absorbance as compared to untreated cells. Likewise, diminished cell viability was not observed in cells treated with diluent control (Fig. 2E). These data indicate that the anti-viral capacity of the SARS-CoV peptides is not a result of cell cytotoxicity, which could directly affect CoV plaque formation.

3.3. Peptides analogous to the loop region of the MHV fusion protein inhibit MHV A59 plaque formation

The potent anti-viral effect observed with the SARS-CoV loop peptides prompted us to test whether peptides analogous to regions located within the loop of the MHV fusion protein had similar anti-viral efficacy. As illustrated in Fig. 1B, the MHV fusion protein also contains five regions of high interfacial hydrophobicity as determined by the WWIHS. Similar to the SARS-CoV fusion protein, two of these regions (MHVWW-III and MHVWW-IV) are located within the MHV S2 loop region. Synthetic peptides corresponding to these two regions (Table 1) were synthesized and examined for their ability to inhibit MHV strain A59 plaque formation on L2 cells at peptide concentrations of ~30 μM. MHVWW-III and MHVWW-IV inhibited viral plaque formation by 22 and 98%, respectively (data not shown). Unlike the synthetic SARS-CoV loop peptides tested (SARSWW-III and SARSWW-IV), only one of the MHV loop peptides (MHVWW-IV) significantly inhibited MHV plaque formation on L2 cells. The potent anti-viral activity of MHVWW-IV is illustrated in Fig. 3. As compared to vehicle-treated controls, MHV plaque efficiency was significantly inhibited in the presence of MHVWW-IV (Fig. 3A versus B). Moreover, similar to the MTT assay results observed with the SARS-CoV peptides, the MHVWW-IV peptide was not cytotoxic at a concentration of 30 μM on L2 cells (data not shown).

Fig. 3
Peptides analogous to the loop region of the MHV S2 subunit inhibit viral plaque formation. L2 cells were infected with ~40 PFU of MHV-A59 following a 1 h incubation with (A) vehicle or 30 μM of (B) MHVWW-IV. Cells were fixed and stained ...

3.4. Peptide-mediated inhibition of CoV plaque formation is dose-dependent

Based on the results presented above, we chose to further examine the inhibitory potential of SARSWW-III, SARSWW-IV and MHVWW-IV, as these peptides achieved levels of inhibition of greater than 70% at concentrations of ~30 μM. Dose–response curves were generated for each peptide, where percent inhibition in viral plaque formation was plotted as function of peptide concentration (Fig. 4). The inhibition efficiency of these peptides was maintainable at low concentrations. The 50% inhibitory concentration (IC50) for both SARSWW-III and SARSWW-IV was approximately 2 μM (Fig. 4A and B). The other SARS-CoV peptides were statistically ineffective at concentrations less than 30 μM (data not shown). Similarly, the IC50 value for MHVWW-IV was 4 μM (Fig. 4C). In addition, the SARS-CoV loop peptides were ineffective inhibitors of MHV infectivity, suggesting some degree of sequence-specific inhibition (data not shown).

Fig. 4
Peptide-mediated inhibition of CoV plaque formation is dose dependent. Vero E6 cells were infected with SARS-CoV following a 1 h incubation with varying concentrations (0.125–60 μM) of (A) SARSWW-III or (B) SARSWW-IV. L2 cells were infected ...

3.5. Circular dichroism analysis of the CoV loop peptide inhibitors

HR peptide inhibitors of SARS-CoV or MHV have α-helical structure and inhibit viral entry through coiled coil interactions (Bosch et al., 2003, 2004; Liu et al., 2004; Zhu et al., 2004). To assess the propensity of the loop peptides studied herein to adopt a defined secondary structure, peptides were examined by CD spectroscopy (Fig. 5). No distinct α-helical (minima at 208 and 222 nm) or β-sheet (minima at ~218 nm) spectra were observed for any of the peptides in 10 mM PO4 buffer pH 7.0. Rather, spectra for all peptides in buffer showed single minima at or near 200 nm indicative of a random coil.

Fig. 5
CoV inhibitory peptides do not assume a defined secondary structure. CD spectra (mean residue ellipticity Θ) of the SARS-CoV peptides: (A) SARSWW-III and (B) SARSWW-IV or the MHV peptide: (C) MHVWW-IV in 10 mM PO4 buffer pH 7.0 at room temperature. ...

4. Discussion

SARSWW-I and SARSWW-II have been independently identified as putative fusion peptides of the SARS-CoV S protein using biophysical approaches (Sainz et al., 2005b). Peptides analogous to class I fusion peptides often have antiviral activity (Gallaher et al., 1992; Owens et al., 1990; Silburn et al., 1998). The observation that WW-I and/or WW-II sequences inhibit infection (Fig. 2A), provides further evidence for their roles in initiating CoV virion:cell fusion; however, it cannot be ruled out that the fusion peptide(s) of SARS-CoV may be in a position different from other class I fusion proteins, e.g. the loop domain (WW-III or WW-IV), and the membrane interactions and conformational changes that CoV S undergoes may not follow the exact same mechanism.

SARSWW-III, SARSWW-IV and MHVWW-IV, which correspond to sequences in the SARS-CoV or MHV loop domain, exhibited antiviral activity greater than the other peptides studied, inhibiting viral plaque formation with IC50 values of 2–4 μM (Figs. 24). Compounds that inhibit virus replication with IC50 in the low μM range can be considered promising lead compounds (Liu et al., 2004; Sia et al., 2002). Inhibition of plaque formation is likely to be the most stringent test of a viral inhibitor. Although different methods were used to quantify the antiviral effects, the IC50 concentrations are similar to or lower than peptide inhibitors corresponding to the HR regions of CoV previously identified. For example, the helical inhibitors described by Bosch et al. (2004) and Liu et al. (2004) exhibited IC50 in the range of 10–40 μM. Further studies are required to define the mechanisms by which the non-helical peptides (SARSWW-III, SARSWW-IV and MHVWW-IV) inhibit CoV infection. We hypothesize that these peptides may sterically hinder the loop, preventing either initial extension of the fusion protein, transition to the six-helix bundle state, or interaction of the S2 subunit with the cellular membrane. A recent study by York and Nunberg (2004) indicated that tryptophan residues in the loop domain of HIV-1 TM are critical for its interactions with the surface glycoprotein (SU), and therefore the inhibitory loop peptides may disrupt analogous S1/S2 region interactions. There is also currently conflicting evidence as to whether or not SARS-CoV S undergoes cleavage to S1 and S2 subunits (Bergeron et al., 2005; Wu et al., 2004).

MHV entry is not sensitive to lysosomotropic agents, and most current evidence indicates that MHV enters the cell through direct fusion with the plasma membrane (de Haan et al., 2004). Simmons et al. (2004) reported that inhibitors of endosomal acidification did impair entry of retroviral pseudotype particles bearing SARS-CoV S. Therefore, the peptide inhibitors identified here may block S-mediated membrane fusion at different steps for SARS-CoV and MHV, at the plasma membrane, within endosomal compartments or both. Alternatively, some inhibitory peptides may interact directly with CoV virions. Further studies are required to elucidate the mechanisms by which SARS-CoV and MHV S peptides inhibit infectivity.

The CoV inhibitory loop peptides identified here did not have a propensity to adopt either an α-helical or β-sheet secondary structure, as determined by circular dichroism analysis (Fig. 5). Increasing the secondary structure, for example by the addition of alanine residues to promote α helix formation (Jayasinghe et al., 2001), may increase their antiviral activities. Studies are currently underway to evaluate this hypothesis, and to investigate other modifications to these CoV inhibitory peptides that may enhance their therapeutic potential.

5. Conclusions

Strategies for the treatment of SARS patients have included broad-spectrum antibiotics, glucocorticoids and ribavirin; however, the efficacy of these treatments is still unclear. Therefore, in order to develop better treatment strategies for future outbreaks, it is imperative to develop new therapeutics. In this study, we provide data to support the further investigation of peptide inhibitors as potential therapeutics for SARS-CoV infection. The immune response to SARS-CoV appears capable, in most individuals, of clearing the infection. Thus, therapeutics that inhibit viral infectivity and reduce SARS-CoV load may extend the window of time during which an effective immune response could arise.

Acknowledgments

This work was supported by the National Institutes of Health (AI054626, AI054238, RR018229, and CA08921; R.F.G.), (GM60000; W.C.W.) and (NO1 AI 25489; C.J.P.). Bruno Sainz is a recipient of a National Research Service Award from the NIAID (AI0543818) and Eric Mossel is a recipient of an Emerging and Re-emerging Diseases Fellowship from the NIAID (AI007536).

References

  • Bergeron E, Vincent MJ, Wickham L, Hamelin J, Basak A, Nichol ST, Chretien M, Seidah NG. Implication of proprotein convertases in the processing and spread of severe acute respiratory syndrome coronavirus. Biochem Biophys Res Commun. 2005;326(3):554–563. [PubMed]
  • Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A. 2004;101(22):8455–8460. [PubMed]
  • Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801–8811. [PMC free article] [PubMed]
  • Cavanagh D, Davis PJ. Coronavirus IBV: removal of spike glycopolypeptide S1 by urea abolishes infectivity and haemagglutination but not attachment to cells. J Gen Virol. 1986;67:1443–1448. [PubMed]
  • de Haan CA, Stadler K, Godeke GJ, Bosch BJ, Rottier PJ. Cleavage inhibition of the murine coronavirus spike protein by a furin-like enzyme affects cell–cell but not virus-cell fusion. J Virol. 2004;78(11):6048–6054. [PMC free article] [PubMed]
  • Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 196776;348(20) [PubMed]
  • FDA notifications. FDA approves Fuzeon, the first fusion inhibitor. AIDS Alert. 2003;18(6):78–79. [PubMed]
  • Gallagher TM, Buchmeier MJ. Coronavirus spike proteins in viral entry and pathogenesis. Virology. 2001;279(2):371–374. [PubMed]
  • Gallaher WR. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell. 1987;50(3):327–328. [PubMed]
  • Gallaher WR. Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses. Cell. 1996;85(4):477–478. [PubMed]
  • Gallaher WR, Ball JM, Garry RF, Griffin MC, Montelaro RC. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses. 1989;5(4):431–440. [PubMed]
  • Gallaher WR, Garry RF. Model of the pre-insertion region of the spike (S2) fusion glycoprotein of the human SARS coronavirus: implications for antiviral therapeutics 2003
  • Gallaher WR, Segrest JP, Hunter E. Are fusion peptides really “sided” insertional helices? Cell. 1992;70(4):531–532. [PubMed]
  • Goldsmith CS, Tatti KM, Ksiazek TG, Rollin PE, Comer JA, Lee WW, Rota PA, Bankamp B, Bellini WJ, Zaki SR. Ultra-structural characterization of SARS coronavirus. Emerg Infect Dis. 2004;10(2):320–326. [PMC free article] [PubMed]
  • Gorbalenya AE, Snijder EJ, Spaan WJ. Severe acute respiratory syndrome coronavirus phylogeny: toward consensus. J Virol. 2004;78(15):7863–7866. [PMC free article] [PubMed]
  • Holmes KV. Structural biology. Adaptation of SARS coronavirus to humans. Science. 2005;309(5742):1822–1823. [PubMed]
  • Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S, Vasilieva N, Dermody TS, Harrison SC, Dormitzer PR, Farzan M, Rottier PJ, Choe H. SARS coronavirus, but not human coronavirus NL63, utilizes Cathepsin L to infect ACE2-expressing cells. J Biol Chem. 2006;281(6):3198–3203. [PubMed]
  • Jayasinghe S, Hristova K, White SH. Energetics, stability, and prediction of transmembrane helices. J Mol Biol. 2001;312(5):927–934. [PubMed]
  • Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, Thomas WD, Jr, Thackray LB, Young MD, Mason RJ, Ambrosino DM, Wentworth DE, Demartini JC, Holmes KV. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A. 2004;101(44):15748–15753. [PubMed]
  • Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4(11):1302–1307. [PubMed]
  • Kliger Y, Levanon EY. Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy. BMC Microbiol. 2003;3(1):20. [PMC free article] [PubMed]
  • Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–1966. [PubMed]
  • Lai MMC, Holmes KV. Coronaviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fundamental Virology. fourth. Lippincott Williams & Wilkins; Philadelphia: 2001.
  • Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 2003a;17(5):691–698. [PubMed]
  • Lalezari JP, Patel IH, Zhang X, Dorr A, Hawker N, Siddique Z, Kolis SJ, Kinchelow T. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol. 2003b;28(2):217–222. [PubMed]
  • Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR., Jr Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A. 1996;93(5):2186–2191. [PubMed]
  • Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864–1868. [PubMed]
  • Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. [PubMed]
  • Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S, Goldsmith CS, Tatti KM, Ksiazek TG, Rollin PE, Comer JA, Lee WW, Rota PA, Bankamp B, Bellini WJ, Zaki SR. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363(9413):938–947. [PubMed]
  • Luytjes W, Sturman LS, Bredenbeek PJ, Charite J, van der Zeijst BA, Horzinek MC, Spaan WJ. Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site. Virology. 1987;161(2):479–487. [PubMed]
  • Magiorkinis G, Magiorkinis E, Paraskevis D, Vandamme AM, Van Ranst M, Moulton V, Hatzakis A. Phylogenetic analysis of the full-length SARS-CoV sequences: evidence for phylogenetic discordance in three genomic regions. J Med Virol. 2004;74(3):369–372. [PubMed]
  • Molloy SS, Bresnahan PA, Leppla SH, Klimpel KR, Thomas G. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem. 1992;267(23):16396–16402. [PubMed]
  • Owens RJ, Tanner CC, Mulligan MJ, Srinivas RV, Compans RW. Oligopeptide inhibitors of HIV-induced syncytium formation. AIDS Res Hum Retroviruses. 1990;6(11):1289–1296. [PubMed]
  • Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003a;361(9366):1319–1325. [PubMed]
  • Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med. 2003b;349(25):2431–2441. [PubMed]
  • Qureshi NM, Coy DH, Garry RF, Henderson LA. Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. AIDS. 1990;4(6):553–558. [PubMed]
  • Richardson CD, Scheid A, Choppin PW. Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides. Virology. 1980;105(1):205–222. [PubMed]
  • Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300(5624):1394–1399. [PubMed]
  • Sainz B, Jr, Rausch JM, Gallaher WR, Garry RF, Wimley WC. The aromatic domain of the coronavirus class I viral fusion protein induces membrane permeabilization: putative role during viral entry. Biochemistry. 2005a;44:947–958. [PubMed]
  • Sainz B, Jr, Rausch JM, Gallaher WR, Garry RF, Wimley WC. Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein. J Virol. 2005b;79(11):7195–7206. [PMC free article] [PubMed]
  • Sia SK, Carr PA, Cochran AG, Malashkevich VN, Kim PS. Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci U S A. 2002;99(23):14664–14669. [PubMed]
  • Siddell SG. The Coronaviridae; an Introduction. Plenum Press; New York, NY: 1995.
  • Silburn KA, McPhee DA, Maerz AL, Poumbourios P, Whittaker RG, Kirkpatrick A, Reilly WG, Manthey MK, Curtain CC. Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion. AIDS Res Hum Retroviruses. 1998;14(5):385–392. [PubMed]
  • Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A. 2004;101(12) [PubMed]
  • Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, Lei LC, Chen QX, Gao YW, Zhou HQ, Xiang H, Zheng HJ, Chern SW, Cheng F, Pan CM, Xuan H, Chen SJ, Luo HM, Zhou DH, Liu YF, He JF, Qin PZ, Li LH, Ren YQ, Liang WJ, Yu YD, Anderson L, Wang M, Xu RH, Wu XW, Zheng HY, Chen JD, Liang G, Gao Y, Liao M, Fang L, Jiang LY, Li H, Chen F, Di B, He LJ, Lin JY, Tong S, Kong X, Du L, Hao P, Tang H, Bernini A, Yu XJ, Spiga O, Guo ZM, Pan HY, He WZ, Manuguerra JC, Fontanet A, Danchin A, Niccolai N, Li YX, Wu CI, Zhao GP. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A. 2005;102(7):2430–2435. [PubMed]
  • Taguchi F. The S2 subunit of the murine coronavirus spike protein is not involved in receptor binding. J Virol. 1995;69(11):7260–7263. [PMC free article] [PubMed]
  • Taguchi F, Shimazaki YK. Functional analysis of an epitope in the S2 subunit of the murine coronavirus spike protein: involvement in fusion activity. J Gen Virol. 2000;81(Pt 12):2867–2871. [PubMed]
  • Tripet B, Howard MW, Jobling M, Holmes RK, Holmes KV, Hodges RS. Structural characterization of the SARS-coronavirus spike S fusion protein core. J Biol Chem. 2004;279(20):20836–20849. [PubMed]
  • Wang P, Chen J, Zheng A, Nie Y, Shi X, Wang W, Wang G, Luo M, Liu H, Tan L, Song X, Wang Z, Yin X, Qu X, Wang X, Qing T, Ding M, Deng H. Expression cloning of functional receptor used by SARS coronavirus. Biochem Biophys Res Commun. 2004;315(2):439–444. [PubMed]
  • Watanabe S, Takada A, Watanabe T, Ito H, Kida H, Kawaoka Y. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol. 2000;74(21):10194–10201. [PMC free article] [PubMed]
  • White SH, Wimley WC. Membrane protein folding and stability: physical principles. Annu Rev Biophys Biomol Struct. 1999;28:319–365. [PubMed]
  • Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell–cell fusion. AIDS Res Hum Retroviruses. 1993;9(11):1051–1053. [PubMed]
  • Wild C, Oas T, McDanal C, Bolognesi D, Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A. 1992;89(21):10537–10541. [PubMed]
  • Wimley WC, White SH. Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat Struct Biol. 1996;3(10):842–848. [PubMed]
  • Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem. 2004;279(5):3197–3201. [PubMed]
  • Wu XD, Shang B, Yang RF, Yu H, Ma ZH, Shen X, Ji YY, Lin Y, Wu YD, Lin GM, Tian L, Gan XQ, Yang S, Jiang WH, Dai EH, Wang XY, Jiang HL, Xie YH, Zhu XL, Pei G, Li L, Wu JR, Sun B. The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells. Cell Res. 2004;14(5):400–406. [PubMed]
  • Xu Y, Liu Y, Lou Z, Qin L, Li X, Bai Z, Pang H, Tien P, Gao GF, Rao Z. Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J Biol Chem. 2004a;279(29):30514–30522. [PubMed]
  • Xu Y, Lou Z, Liu Y, Pang H, Tien P, Gao GF, Rao Z. Crystal structure of SARS-CoV spike protein fusion core. J Biol Chem. 2004b;1(1):1.
  • Xu Y, Zhu J, Liu Y, Lou Z, Yuan F, Cole DK, Ni L, Su N, Qin L, Li X, Bai Z, Bell JI, Pang H, Tien P, Gao GF, Rao Z. Characterization of the Heptad Repeat Regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. Biochemistry. 2004c;43(44):14064–14071. [PubMed]
  • York J, Nunberg JH. Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41. J Virol. 2004;78(9):4921–4926. [PMC free article] [PubMed]
  • Young JK, Li D, Abramowitz MC, Morrison TG. Interaction of peptides with sequences from the Newcastle disease virus fusion protein heptad repeat regions. J Virol. 1999;73(7):5945–5956. [PMC free article] [PubMed]
  • Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem Biophys Res Commun. 2004;319(3):746–752. [PubMed]
  • Zhu J, Xiao G, Xu Y, Yuan F, Zheng C, Liu Y, Yan H, Cole DK, Bell JI, Rao Z, Tien P, Gao GF. Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem Biophys Res Commun. 2004;319(1):283–288. [PubMed]